Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: The expansion makes Turbhe more competitive for high-potency peptides, HPAPIs, and biomolecules, helping Piramal attract programs that need safe, sm...
Latest Developments in Cell and Gene Therapy Manufacturing Cell and gene therapies are rapidly emerging as one of the most transformative areas in modern medicine. These advanced therapies aim t...
Latest Developments in the Biosimilar Market The global pharmaceutical industry is witnessing rapid growth in the biosimilars market as patents for several blockbuster biologic drugs begin to ex...
